Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Alfa-2b in Stage III Melanoma (Russia)
NCT02155322Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2014
- Primary completion
- Mar 2016
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2b in melanoma, sponsored by Merck & Co. Primary endpoints: Percentage of Participants Experiencing Adverse Events up to 13 months and Percentage of Participants Discontinuing Study Drug Because of AEs up to 12 months. Started Aug 2014; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02155322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02155322.